282,249 Shares in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Purchased by Altium Capital Management LLC

Altium Capital Management LLC bought a new stake in Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) during the 4th quarter, HoldingsChannel reports. The fund bought 282,249 shares of the company’s stock, valued at approximately $184,000. Altium Capital Management LLC owned approximately 0.06% of Quoin Pharmaceuticals at the end of the most recent reporting period.

Separately, Apollon Wealth Management LLC acquired a new stake in shares of Quoin Pharmaceuticals during the 4th quarter worth approximately $52,000. Hedge funds and other institutional investors own 8.63% of the company’s stock.

Quoin Pharmaceuticals Price Performance

Shares of NASDAQ:QNRX opened at $5.48 on Friday. The company’s 50 day simple moving average is $9.47 and its 200 day simple moving average is $17.07. Quoin Pharmaceuticals, Ltd. has a 1 year low of $5.01 and a 1 year high of $54.95. The stock has a market capitalization of $3.23 million, a price-to-earnings ratio of -1.35 and a beta of 1.89.

Quoin Pharmaceuticals (NASDAQ:QNRX) last issued its quarterly earnings results on Thursday, March 13th. The company reported ($12.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($17.50) by $5.25. As a group, analysts anticipate that Quoin Pharmaceuticals, Ltd. will post -2.05 EPS for the current fiscal year.

Quoin Pharmaceuticals Company Profile

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma.